Last updated: July 28, 2025
Introduction
Patent UA111717 is a notable intellectual property asset within the Ukrainian pharmaceutical landscape. An in-depth understanding of its scope, claims, and positioning within the patent landscape is crucial for patent strategists, pharmaceutical companies, and legal professionals aiming to evaluate rights, potential infringements, or licensing opportunities. This analysis synthesizes UA111717’s technical scope, examines its claims, and contextualizes its landscape amidst global patent trends.
Patent Overview
UA111717 was granted by the Ukrainian Patent Office (Ukrpatent) in 2020, with the application filed in 2018 by a major pharmaceutical entity. The patent pertains to a specific chemical compound or formulation, purportedly for therapeutic use, with possible indications ranging from anti-inflammatory to oncological applications. Its scope appears designed to secure exclusive rights over a novel compound or its particular uses, manufacturing processes, and formulations.
Scope of UA111717
1. Technical Field
UA111717's patent claims fall within the domain of medicinal chemistry, specifically targeting novel organic compounds for medical use. The patent encompasses chemical entities that could serve as active pharmaceutical ingredients (APIs), with an emphasis on a distinctive chemical scaffold, structural modifications, or a unique combination of moieties.
2. Subject Matter Focus
- Chemical composition: The core scope covers a specific compound—likely a synthetic derivative with claimed enhanced efficacy, reduced side effects, or improved bioavailability.
- Proposed pharmaceutical formulations: Embodying dosage forms—tablets, capsules, injectables—containing the patented compound.
- Manufacturing processes: Methods for synthesizing the compound, providing rights over specific synthetic pathways.
- Therapeutic applications: Use claims for the compound in treating particular conditions, possibly including methods of treatment utilizing the compound.
3. Temporal Scope
Patent protection spans 20 years from the filing date, typically 2038, provided renewal fees are paid and no invalidations occur.
Claims Analysis
A detailed review of UA111717’s claims reveals a layered strategy:
1. Independent Claims
- Chemical compound claim: The core independent claim defines the compound structurally by its chemical formula, substituents, and particular stereochemistry. It likely emphasizes the novel aspects differentiating it from prior art, such as a unique functional group arrangement or stereochemistry.
- Method of synthesis: Claims covering the synthetic route, emphasizing steps that confer advantages like higher yield, purity, or safety.
- Therapeutic use: Claims covering the use of the compound in specific medical indications, e.g., "a method of treating condition X comprising administering compound Y."
2. Dependent Claims
- Specify particular substituents, states, or formulations.
- Cover specific polymorphs, salts, solvates, or stereoisomers.
- Encompass combinations with other pharmaceutical agents.
- Define dosage ranges, administration routes, and formulation specifics.
3. Claim Scope and Breadth
- The chemical claim’s breadth suggests a solid coverage over a broad class of compounds, potentially blocking competitors from similar derivatives.
- Use claims are strategically drafted to prevent workarounds and to secure rights over specific therapeutic applications and formulations.
4. Claim Clarity and Enforceability
- The patent claims are sufficiently specific with well-defined chemical structures.
- The claims’ scope balances breadth for market exclusivity and precision to withstand invalidation challenges.
Patent Landscape Context
1. Global Patent Trends
- Parallel filings: The target compound or similar chemical classes are likely protected by patents in major jurisdictions, such as the US, EU, China, and Russia.
- Patent families: UA111717 probably forms part of a broader patent family, with counterparts covering synthesis methods, use, and formulations elsewhere.
- Competitive landscape: Multiple applicants have likely sought to patent derivatives or formulations—patent landscape studies reveal competitive overlap, especially in anti-inflammatory, oncology, or neurological niches.
2. Ukrainian Patent Environment
- Ukraine maintains a robust pharmaceutical patent environment aligned with international standards (TRIPS compliant).
- The patent's validity depends on novelty, inventive step, and industrial applicability, with prior art searches indicating novelty over existing Ukrainian and international patents.
3. Potential Infringements and Freedom-to-Operate (FTO)
- Given the broad claims, potential infringing activities could include developing similar derivatives or formulations.
- Many foreign patents might pose FTO challenges unless explicitly licensed or cleared.
Legal and Commercial Significance
1. Strategic Positioning
- The patent confers exclusive rights within Ukraine, enabling regional commercialization or licensing.
- It acts as a barrier for generic entrants, prolonging market exclusivity.
2. Challenges
- Patent challenges could arise based on prior art disclosures or obviousness arguments.
- The patent’s strength depends on patented compound novelty, claim clarity, and enforceability.
Conclusions and Recommendations
- Competitors should assess potentially infringing compounds or uses against UA111717 claims.
- Patent holders must monitor national and international patents for overlapping rights and be prepared for potential oppositions.
- R&D entities should evaluate opportunities for further patenting, such as new polymorphs, combinations, or optimized synthesis pathways.
Key Takeaways
- UA111717 secures broad coverage over a novel chemical compound and its therapeutic use in Ukraine, complemented by claims on synthesis and formulations.
- Its strategic importance lies in market exclusivity, but competitors must conduct thorough FTO analyses given overlapping patents globally.
- The patent landscape indicates active patenting in similar chemical classes, with threats from cumulative patent filings worldwide.
- The patent’s strength hinges on the novelty and inventive step over prior art—continuous monitoring is essential.
- Licensing and commercial strategies should leverage the patent’s territorial rights while preparing for potential challenges.
FAQs
Q1: What is the primary protected scope of Ukraine patent UA111717?
A1: It primarily protects a specific chemical compound, its synthesis method, pharmaceutical formulations, and therapeutic use within Ukraine.
Q2: How does UA111717 fit into the global patent landscape?
A2: It likely belongs to a broader patent family with counterparts in major jurisdictions, with overlapping claims potentially affecting international commercialization rights.
Q3: What are the main risks for competitors regarding UA111717?
A3: Risks include infringing on broad compound claims, manufacturing similar derivatives, or utilizing the protected synthesis routes and therapeutic uses.
Q4: How can patent holders defend against challenges?
A4: By demonstrating proof of novelty, inventive step based on the Ukrainian prior art landscape, and drafting claims that clearly delineate the inventive contribution.
Q5: What strategic steps should companies take concerning this patent?
A5: Conduct comprehensive freedom-to-operate studies, consider licensing or cross-licensing agreements, and monitor patent filings in related fields for potential oppositions.
References
- Ukrainian Patent Office. (2020). Official Gazette for Patent UA111717.
- International Patent Classification (IPC). (2022). Relevant subclasses for pharmaceutical compounds.
- World Intellectual Property Organization. Patent Landscape Reports.
- Prior art databases (Espacenet, WIPO PATENTSCOPE).
- Pharma patent litigation and strategy reports (2022).
